日本：第二剂 SARS-CoV-2 疫苗接种后发生与纳武利尤单抗相关的 1 型糖尿病
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
出版信息
Emerg Infect Dis. 2022 Jul;28(7):1518-1520. doi: 10.3201/eid2807.220127. Epub 2022 Apr 25.
Abstract
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
摘要
最近，随着免疫检查点抑制剂（如纳武利尤单抗）的使用日益增多，包括 1 型糖尿病在内的免疫相关不良反应已成为一个严重的问题。我们报告了 1 例患者在接受第 2 剂基于 mRNA 的 SARS-CoV-2 疫苗接种后发生免疫检查点抑制剂相关 1 型糖尿病。
Zotero 插件